spironolactone has been researched along with abiraterone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arlt, W; Attard, G; Carreira, S; de Bono, JS; Goodall, J; Hay, CW; Lim, AC; McEwan, IJ; Nowakowska, K; Pezaro, C; Richards, J; Taylor, AE; Wingate, A | 1 |
| Collado-Borrell, R; Escudero-Vilaplana, V; Herranz, A; López-López, C; Revuelta-Herrero, JL; Ruiz-Briones, P; Sanjurjo, M; Somoza-Fernández, B; Vicente-Valor, J; Villanueva-Bueno, C | 1 |
2 other study(ies) available for spironolactone and abiraterone
| Article | Year |
|---|---|
Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
Topics: Androgen Receptor Antagonists; Androgens; Androstenes; Androstenols; Anilides; Benzamides; Binding, Competitive; Cell Line, Tumor; Drug Interactions; Eplerenone; Humans; Male; Metribolone; Nitriles; Phenylthiohydantoin; Prednisolone; Prostatic Neoplasms; Receptors, Androgen; Spironolactone; Tosyl Compounds | 2012 |
Potential negative pharmacodynamic interaction of spironolactone and abiraterone in two prostate cancer patients.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Spironolactone; Treatment Outcome | 2022 |